Objectives: To demonstrate the pattern of disease-modifying antirheumatic drugs (DMARDs) use in Saudi and non-Saudi rheumatoid arthritis (RA) patients, and to evaluate the association of DMARDs use with anti-mutated citrullinated vimentin (anti-MCV) positivity and other factors.
Methods: Retrospectively, for a period of 7 years (2007-2014), we studied 205 RA patients, at King Abdulaziz University Hospital (KAUH), Jeddah, Saudi Arabia. All patients used DMARDs. Pattern of use for all 6 DMARDs was almost the same among Saudis and non-Saudis with no significant difference (p>0.05) for each DMARD; MTX was the most commonly used DMARD (71-76%).
Results: There was no association between anti-MCV positivity and different DMARDs use. Methotrexate was used 76 times as combination, scoring the highest in this respect. There was a significant correlation (p<0.05) between Plaquenil with Methotrexate and with Sulfasalazine; Leflunomide with anti-TNF and with Prednisolone; age with Methotrexate and with Plaquenil; anti-MCV positivity with Prednisolone. Saudi/non-Saudi status showed no correlation with all factors or drugs. There was no significant association between DMARDs and comorbidity.
Conclusion: Similar to worldwide results, MTX was the most commonly used DMARD; with the addition of anti-TNF to increase the effect, and folic acid to minimize the side effects. In this cohort, the pattern of use for all DMARDs was similar among Saudis and non-Saudis; treatment depended neither on anti-MCV positivity nor on the presence of comorbid conditions. A study of the association of DMARDs with disease activity is recommended.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381016 | PMC |
| http://dx.doi.org/10.15537/smj.2015.3.10208 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objectives: We aimed to assess the anti-mutated citrullinated vimentin (anti-MCV) antibodies in RA patients' serum and to explore their association with interstitial lung disease (ILD).
Methods: Eighty rheumatoid arthritis (RA) patients and forty healthy controls were included in this case-control study. Of these patients, forty had ILD, and forty without ILD.
Evaluation of the clinical performance of anti-mutated citrullinated vimentin antibody and 14-3-3 eta testing in rheumatoid arthritis.
Clin Chem Lab Med
November 2024
ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA.
Objectives: Early rheumatoid arthritis (RA) detection is crucial for improving patient prognosis. Anticyclic citrullinated peptide antibodies (anti-CCP) and rheumatoid factors (RF) support RA diagnosis but are undetectable in ∼20 % of cases. Recently, antibodies against mutated citrullinated vimentin (anti-MCV) and detection of 14-3-3 eta have emerged with implications for preclinical RA diagnosis and monitoring treatment.
View Article and Find Full Text PDFAutoantibodies Serum Level and 10-Year Risk of Fractures Evaluated by FRAX Tool in Rheumatoid Arthritis Patients.
Open Access Rheumatol
July 2024
Department of Rheumatology, Farhat Hached Hospital, Sousse, Tunisia.
Purpose: FRAX is a tool used for evaluation of risk of fracture in RA and non-RA patients and to identify those eligible for intervention. One of the limitations of FRAX in RA settings is that it does not consider factors known to contribute to osteoporosis such as autoantibodies. This study analysed the association of anti-mutated citrullinated vimentin antibody (anti-MCV), anti-cyclic citrullinated peptide antibody (anti-CCP), IgM rheumatoid factor (RF), IgA RF with 10-year risk of major osteoporosis and hip fracture.
View Article and Find Full Text PDFExpression and diagnostic value of interleukin-22 in rheumatoid arthritis-associated interstitial lung disease.
Int Immunopharmacol
June 2024
Department of Rheumatology and Immunology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221005, Jiangsu Province, China. Electronic address:
Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is characterized by a high incidence and mortality rate, highlighting the need for biomarkers to detect ILD early in RA patients. Previous studies have shown the protective effects of Interleukin-22 (IL-22) in pulmonary fibrosis using mouse models. This study aims to assess IL-22 expression in RA-ILD to validate foundational experiments and explore its diagnostic value.
View Article and Find Full Text PDFClinical significance of anti-mutated citrullinated vimentin antibodies in rheumatoid arthritis patients.
Hum Antibodies
June 2024
Department Rheumatology, Rehabilitation, and Physical Medicine, Faculty of Medicine Alexandria University, Alexandria, Egypt.
Background: Anti-mutated citrullinated vimentin (MCV) antibodies have recently been recommended as a better arthritis diagnostic marker.
Objectives: To investigate the association between anti-MCV antibodies and the clinical, functional, and radiographic characteristics of rheumatoid arthritis (RA) patients.
Methods: This case-control study was conducted on 40 RA patients and 40 healthy subjects.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!